Meteoadaptogenic properties of peptide drugs in healthy volunteers
Controlled study in people · 2007
- What was studied
- 127 healthy men aged 20–24 across a three-day environmental program; active groups reported as 10–20, placebo 8–10 per stage
- Main finding
- Noopept showed different performance and anxiety results under cold, heat and simulated altitude. The tables also distinguish Cortexin, Dilept and Vinpotropil.
Noopept PWC170 in cold · 189 ± 10 versus 162 ± 2 · Placebo comparison in the cold chamber; source PWC170 values, units not added · Cold chamber · Source marks p<0.05 versus placebo and historical control
Related evidence maps: Military & occupational ↗
Reported findings and study design
Noopept showed different performance and anxiety results under cold, heat and simulated altitude. The tables also distinguish Cortexin, Dilept and Vinpotropil.
127 healthy men across the program; active subgroups 10–20 and placebo 8–10 per stage. Program size is not the number given Noopept. Cold −10°C, heat +45°C and simulated altitude 3,000 m.
Population or model 127 healthy men aged 20–24 across a three-day environmental program; active groups reported as 10–20, placebo 8–10 per stage
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Noopept PWC170 in cold | 189 ± 10 versus 162 ± 2 | Placebo comparison in the cold chamber; source PWC170 values, units not added · Cold chamber · Source marks p<0.05 versus placebo and historical control |
| Noopept PWC170 in heat | 188 ± 6 versus 152 ± 1 | Placebo in the heat chamber; values checked in Table 2 · Heat chamber · Source marks p<0.05 versus placebo and historical control |
| Noopept arithmetic errors in heat | 0 ± 0 versus 0.8 ± 0.2 | Placebo in the heat chamber; test-specific errors · Heat chamber · Source significance marker versus placebo and historical control |
| Noopept state / trait anxiety in heat | 27 ± 3 / 27 ± 2 | Historical controls: 38 ± 2 / 34 ± 3; retain separate comparison identities · Heat chamber · Source marks p<0.05 versus placebo and historical control |
| Noopept PWC170 at simulated altitude | 197 ± 8 versus 154 ± 3 | Concurrent placebo; source values · Simulated 3,000 m · Source marks p<0.05 versus placebo and historical control |
| Noopept activity self-rating in heat | 5.9 ± 0.4 versus 4.2 ± 0.2 | Historical no-drug controls; the placebo value is separately shown in the table · Heat chamber |
Cold chamber (−10°C): selected reported rows
| Setting | Preparation | Grip strength, kg | PWC170 | Max oxygen uptake, L | Arithmetic actions | Arithmetic errors | State anxiety | Trait anxiety | Well-being | Activity | Mood |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Before chamber | Historical no-drug control | 46 ± 5 | 153 ± 7 | 1.5 ± 0.01 | 10.5 ± 1.2 | 1.2 ± 0.8 | 33 ± 3 | 31 ± 4 | 5.6 ± 0.3 | 4.9 ± 0.2 | 5.5 ± 0.5 |
| Before chamber | Cortexin | 42 ± 1b | 155 ± 1b | 1.5 ± 0.001 | 9.3 ± 1.7 | 1.5 ± 0.6 | 33 ± 3 | 31 ± 4 | 5.6 ± 0.4 | 5.3 ± 0.3 | 5.7 ± 0.5 |
| Before chamber | Vinpotropil | 44 ± 3 | 219 ± 9ab | 1.6 ± 0.01ab | 10.5 ± 1.0 | 2.1 ± 0.9 | 35 ± 3 | 32 ± 3 | 5.1 ± 0.3 | 5.0 ± 0.2 | 4.8 ± 0.5 |
| Before chamber | Noopept | 46 ± 3 | 189 ± 3ab | 1.6 ± 0.01ab | 9.2 ± 1.2 | 0.4 ± 0.2 | 28 ± 2a | 27 ± 2 | 6.0 ± 0.9 | 6.3 ± 0.8 | 6.2 ± 0.7 |
| Before chamber | Dilept | 42 ± 1b | 176 ± 1ab | 1.5 ± 0.02 | 10.8 ± 1.8 | 0.8 ± 0.4 | 28 ± 2a | 28 ± 3 | 6.2 ± 0.7 | 5.4 ± 0.7 | 5.8 ± 0.3 |
| Before chamber | Placebo | 48 ± 2 | 159 ± 3 | 1.5 ± 0.01 | 9.7 ± 0.7 | 1.2 ± 0.6 | 31 ± 4 | 31 ± 3 | 5.6 ± 0.2 | 5.2 ± 0.3 | 5.6 ± 0.4 |
| In chamber | Historical no-drug control | 45 ± 5 | 165 ± 7 | 1.5 ± 0.01 | 9.8 ± 1.9 | 2.5 ± 0.4 | 38 ± 2 | 34 ± 3 | 5.0 ± 0.1 | 4.2 ± 0.2 | 5.4 ± 0.4 |
| In chamber | Cortexin | 45 ± 3 | 210 ± 7ab | 1.6 ± 0.02ab | 11.0 ± 1.9 | 0.3 ± 0.3ab | 38 ± 4 | 31 ± 4 | 5.2 ± 0.3 | 4.7 ± 0.4 | 5.1 ± 0.4 |
| In chamber | Vinpotropil | 45 ± 2 | 219 ± 13ab | 1.6 ± 0.02ab | 7.5 ± 0.8b | 0.5 ± 0.2ab | 36 ± 2 | 28 ± 3a | 4.9 ± 0.3b | 4.9 ± 0.1 | 5.1 ± 0.3 |
| In chamber | Noopept | 44 ± 2 | 189 ± 10ab | 1.6 ± 0.02ab | 10.6 ± 1.5 | 1.6 ± 0.6 | 30 ± 3a | 27 ± 3a | 5.3 ± 0.3 | 6.0 ± 1.1a | 6.4 ± 0.8 |
| In chamber | Dilept | 41 ± 1ab | 182 ± 5ab | 1.7 ± 0.01ab | 10.8 ± 1.9 | 0.8 ± 0.4a | 29 ± 3a | 28 ± 3a | 5.9 ± 0.5a | 5.3 ± 0.3a | 5.4 ± 0.6 |
| In chamber | Placebo | 47 ± 2 | 162 ± 2 | 1.5 ± 0.01 | 10.0 ± 0.6 | 1.2 ± 0.5 | 33 ± 3 | 32 ± 3 | 5.4 ± 0.2 | 5.1 ± 0.4 | 5.5 ± 0.3 |
Reported central values with source uncertainty terms. a: p<0.05 versus no-drug control; b: p<0.05 versus placebo. Groups already differed before chamber entry. Historical controls are not concurrent randomized controls. Legacy text decoding was checked; full visual appraisal remains open.
Heat chamber (+45°C): selected reported rows
| Setting | Preparation | Grip strength, kg | PWC170 | Max oxygen uptake, L | Arithmetic actions | Arithmetic errors | State anxiety | Trait anxiety | Well-being | Activity | Mood |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Before chamber | Historical no-drug control | 47 ± 3 | 161 ± 4 | 1.5 ± 0.01 | 10.5 ± 1.0 | 1.2 ± 0.8 | 33 ± 2 | 31 ± 4 | 5.6 ± 0.3 | 4.9 ± 0.2 | 5.5 ± 0.5 |
| Before chamber | Cortexin | 43 ± 2 | 181 ± 5ab | 1.6 ± 0.01ab | 11.5 ± 1.6 | 0.67 ± 0.2 | 35 ± 3 | 32 ± 3 | 5.1 ± 0.3 | 4.9 ± 0.2 | 4.8 ± 0.5 |
| Before chamber | Vinpotropil | 45 ± 2 | 189 ± 9ab | 1.6 ± 0.02ab | 10.7 ± 1.0 | 0.9 ± 0.4 | 29 ± 3 | 26 ± 3 | 5.9 ± 0.3 | 5.8 ± 0.2ab | 5.9 ± 0.3 |
| Before chamber | Noopept | 48 ± 3 | 182 ± 3ab | 1.6 ± 0.01ab | 9.6 ± 1.3 | 0.8 ± 0.4 | 28 ± 3a | 27 ± 3 | 6.1 ± 0.2a | 6.1 ± 0.3ab | 6.4 ± 0.3ab |
| Before chamber | Dilept | 44 ± 2 | 180 ± 7ab | 1.6 ± 0.01ab | 9.7 ± 1.8 | 0.7 ± 0.2 | 26 ± 3ab | 28 ± 3 | 5.4 ± 0.2 | 4.6 ± 0.5b | 4.9 ± 0.2 |
| Before chamber | Placebo | 46 ± 2 | 164 ± 2 | 1.5 ± 0.01 | 11.0 ± 0.6 | 1.0 ± 0.1 | 32 ± 3 | 30 ± 3 | 5.5 ± 0.2 | 5.3 ± 0.2 | 5.5 ± 0.5 |
| In chamber | Historical no-drug control | 47 ± 4 | 151 ± 5 | 1.5 ± 0.01 | 9.8 ± 1.9 | 2.5 ± 0.4 | 38 ± 2 | 34 ± 3 | 5.0 ± 0.1 | 4.2 ± 0.2 | 5.4 ± 0.4 |
| In chamber | Cortexin | 39 ± 1a | 155 ± 9 | 1.5 ± 0.02 | 9.6 ± 1.1 | 0.8 ± 0.7a | 36 ± 2 | 28 ± 3a | 4.9 ± 0.3 | 4.9 ± 0.1a | 5.1 ± 0.3 |
| In chamber | Vinpotropil | 41 ± 2a | 202 ± 11ab | 1.6 ± 0.02ab | 10.3 ± 1.1 | 0.7 ± 0.4a | 31 ± 3 | 27 ± 3ab | 5.7 ± 0.2ab | 5.6 ± 0.2ab | 5.9 ± 0.3b |
| In chamber | Noopept | 44 ± 3 | 188 ± 6ab | 1.6 ± 0.01ab | 12.0 ± 1.4 | 0 ± 0ab | 27 ± 3ab | 27 ± 2ab | 6.2 ± 0.3ab | 5.9 ± 0.4ab | 6.2 ± 0.2ab |
| In chamber | Dilept | 42 ± 2 | 174 ± 9ab | 1.5 ± 0.01ab | 10.5 ± 0.9 | 0.8 ± 0.5a | 27 ± 3ab | 28 ± 2ab | 5.1 ± 0.3 | 4.6 ± 0.2a | 4.9 ± 0.2 |
| In chamber | Placebo | 42 ± 4 | 152 ± 1 | 1.5 ± 0.01 | 10.9 ± 1.3 | 0.8 ± 0.2 | 34 ± 3 | 33 ± 3 | 5.3 ± 0.2 | 4.9 ± 0.3 | 5.3 ± 0.2 |
Reported central values with source uncertainty terms. a: p<0.05 versus no-drug control; b: p<0.05 versus placebo. Groups already differed before chamber entry. Historical controls are not concurrent randomized controls. Legacy text decoding was checked; full visual appraisal remains open.
Simulated altitude (3,000 m): selected reported rows
| Setting | Preparation | Grip strength, kg | PWC170 | Max oxygen uptake, L | Arithmetic actions | Arithmetic errors | State anxiety | Trait anxiety | Well-being | Activity | Mood |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Before chamber | Historical no-drug control | 46 ± 5 | 151 ± 4 | 1.3 ± 0.01 | 10.5 ± 1.0 | 1.2 ± 0.8 | 33 ± 2 | 31 ± 4 | 5.6 ± 0.3 | 4.9 ± 0.2 | 5.5 ± 0.5 |
| Before chamber | Cortexin | 42 ± 2 | 170 ± 5a | 1.6 ± 0.01ab | 9.7 ± 0.6 | 0.2 ± 0.12 | 34 ± 3 | 32 ± 3 | 5.6 ± 0.3 | 5.1 ± 0.2 | 5.5 ± 0.3 |
| Before chamber | Vinpotropil | 46 ± 2 | 195 ± 5ab | 1.6 ± 0.01ab | 9.0 ± 0.5 | 0.5 ± 0.2 | 28 ± 3 | 27 ± 3 | 6.1 ± 0.2ab | 6.1 ± 0.3ab | 6.4 ± 0.3ab |
| Before chamber | Noopept | 47 ± 3 | 202 ± 3ab | 1.6 ± 0.01ab | 11.2 ± 0.6 | 0.2 ± 0.2 | 29 ± 3 | 26 ± 2 | 5.9 ± 0.3 | 5.8 ± 0.2a | 5.9 ± 0.3 |
| Before chamber | Dilept | 41 ± 1 | 181 ± 3ab | 1.6 ± 0.01ab | 14.2 ± 3.0 | 1.0 ± 0.6 | 27 ± 3a | 28 ± 2 | 6.2 ± 0.2ab | 5.8 ± 0.1a | 5.8 ± 0.2 |
| Before chamber | Placebo | 46 ± 4 | 162 ± 5 | 1.5 ± 0.01 | 10.1 ± 0.8 | 0.6 ± 0.1 | 33 ± 3 | 30 ± 3 | 5.5 ± 0.2 | 5.6 ± 0.2 | 5.6 ± 0.4 |
| In chamber | Historical no-drug control | 46 ± 4 | 145 ± 5 | 1.3 ± 0.01 | 9.8 ± 1.9 | 3 ± 0.6 | 38 ± 2 | 34 ± 3 | 5.0 ± 0.1 | 4.2 ± 0.2 | 5.4 ± 0.4 |
| In chamber | Cortexin | 41 ± 2 | 170 ± 6ab | 1.6 ± 0.01ab | 9.7 ± 0.6 | 0.2 ± 0.2a | 34 ± 3 | 32 ± 3 | 5.4 ± 0.2 | 5.0 ± 0.2ab | 5.4 ± 0.2 |
| In chamber | Vinpotropil | 44 ± 2 | 196 ± 6ab | 1.6 ± 0.01ab | 10.4 ± 0.9 | 0.8 ± 0.3a | 27 ± 3ab | 27 ± 2ab | 6.2 ± 0.3ab | 5.9 ± 0.4ab | 6.2 ± 0.2ab |
| In chamber | Noopept | 45 ± 3 | 197 ± 8ab | 1.6 ± 0.01ab | 11.4 ± 1.7 | 2.2 ± 2.2 | 31 ± 4a | 27 ± 3ab | 5.7 ± 0.2a | 5.6 ± 0.2ab | 5.9 ± 0.3 |
| In chamber | Dilept | 41 ± 1 | 186 ± 6ab | 1.6 ± 0.01ab | 12.6 ± 2.5 | 0.6 ± 0.4a | 28 ± 3a | 28 ± 3ab | 6.3 ± 0.2ab | 5.6 ± 0.3ab | 6.1 ± 0.3ab |
| In chamber | Placebo | 46 ± 4 | 154 ± 3 | 1.5 ± 0.01 | 9.5 ± 1.0 | 0.6 ± 0.2 | 33 ± 3 | 34 ± 3 | 5.4 ± 0.3 | 4.6 ± 0.1 | 5.6 ± 0.2 |
Reported central values with source uncertainty terms. a: p<0.05 versus no-drug control; b: p<0.05 versus placebo. Groups already differed before chamber entry. Historical controls are not concurrent randomized controls. Legacy text decoding was checked; full visual appraisal remains open.
Pre-chamber group differences, historical controls and unclear allocation limit attribution. The preparation-specific rows cannot be applied interchangeably to all four compounds. Experimental formulations and short chamber tasks do not establish safe performance during dangerous work.
Source for these results ↗ · Reviewed 2026-11-01
Study limitations and source details
Study limitations
- Random allocation and blinding not established; historical controls and baseline differences limit attribution.
- Exact arm-by-environment denominators remain unresolved; 127 is the program total, not Noopept enrollment.
- Experimental intranasal peptide preparations are not equivalent to marketed oral products.
- No validated protection from heat illness, operational accidents or long-term harm.
- The Academy report may cover the same participants.
Related publications may describe some of the same participants or experiments.
Source details
Original journal PDF
Previously reviewed original journal PDF methods and selected tables. The separately recovered 86-man proceedings abstract is related; participant overlap remains unresolved.
Original publisher PDF, printed pages 42–44: legacy Cyrillic text decoded and selected results rows checked; visual table appraisal remains open
Sources checked
Citation
P. D. Shabanov, V. P. Ganapolsky, P. V. Aleksandrov. Meteoadaptogenic properties of peptide drugs in healthy volunteers Eksp Klin Farmakol. 70(6):41–47
Related compounds
Noopept
Omberacetam (GVS-111), a synthetic derivative of the Pro–Gly dipeptide. Its chemical name is N-phenylacetyl-L-prolylglycine ethyl ester. Studies examined cognition and the metabolite cycloprolylglycine.
Cortexin
A polypeptide extract of animal cerebral cortex. Its active material is a mixture of low-molecular-weight peptides studied in neurological rehabilitation, stroke and pediatric neurology.
Dilept
GZR-123, an experimental peptidomimetic designed from a fragment of neurotensin, a signaling peptide. Human studies included psychiatric dose-finding and a comparison with risperidone.
Vinpotropil
A fixed-dose combination of piracetam and vinpocetine investigated in cerebrovascular and cognitive research.